Search results for "obstetric"

showing 10 items of 2144 documents

Concomitant gonadotropin-releasing hormone agonist and menotropin treatment for the synchronized induction of multiple follicles.

1988

In an effort to overcome possible interference by endogenous gonadotropin-ovarian hormone dynamics, desensitization of the pituitary gonadotropins by a gonadotropin-releasing hormone agonist (GnRHa) was achieved in 12 women with repeatedly failed attempts at multiple follicular stimulation. Eight women were scheduled for in vitro fertilization (IVF) and embryo transfer (ET), and 4 for gamete intrafallopian transfer (GIFT). Stimulation failure was characterized by premature luteinization, poor estradiol (E2) response, or inadequate follicular growth. The agonist was administered by nasal spray 500 to 600 micrograms/day beginning on days 21 to 23 of the menstrual cycle. A rapid desensitizatio…

AgonistAdultendocrine systemmedicine.medical_specialtyMenotropinsmedicine.drug_classmedia_common.quotation_subjectmedicine.medical_treatmentFertilization in VitroBiologyBuserelinReproductive TechniquesOvulation InductionInternal medicineGonadotropin-releasing hormone agonistFollicular phasemedicineHumansGamete intrafallopian transferMenstrual cyclemedia_commonIn vitro fertilisationObstetrics and GynecologyEmbryo TransferEmbryo transferEndocrinologyReproductive MedicineFemaleMenotropinhormones hormone substitutes and hormone antagonistsFertility and sterility
researchProduct

Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist…

2005

Background This descriptive study evaluates the impact on endometrial development of standard and high doses of a GnRH antagonist in stimulated cycles compared with GnRH agonist and natural cycles. Methods Thirty-one oocyte donors were treated with a combination of rFSH and 0.25 mg/day ganirelix (standard dose), 2 mg/day ganirelix (high dose) or 0.6 mg/day buserelin (long protocol). Vaginal progesterone (200 mg/day) was administered in the luteal phase. Endometrial biopsies were performed 2 and 7 days after HCG administration. Additional biopsies were carried out in a subset of 12 subjects, 2 and 7 days following the LH peak of their previous natural cycle. Biopsies were evaluated histologi…

AgonistAdultendocrine systemmedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classmedicine.medical_treatmentFertilization in VitroLuteal phaseBiologyLuteal PhaseEndometriumBuserelinChorionic GonadotropinGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneEndometriumOvulation InductionInternal medicinemedicineHumansUltrasonicsGanirelixOligonucleotide Array Sequence Analysismedicine.diagnostic_testOocyte DonationRehabilitationObstetrics and GynecologyBuserelinmedicine.anatomical_structureEndocrinologyReproductive MedicineGene Expression RegulationReceptors EstrogenMicroscopy Electron ScanningOocytesRNAOvulation inductionFemaleFollicle Stimulating HormoneReceptors Progesteronehormones hormone substitutes and hormone antagonistsmedicine.drugEndometrial biopsyHuman reproduction (Oxford, England)
researchProduct

Pretreatment with gonadotropin-releasing hormone (GnRH) antagonists to prevent the flare-up effect of long-acting GnRH agonists: results of a pilot s…

2007

This study evaluated in vivo whether the flare-up effect of GnRH agonists can be suppressed through pretreatment with a GnRH antagonist. The classic flare-up effect caused by 3.8 mg goserelin acetate could not be suppressed through pretreatment using a single dosage of 3.24 mg cetrorelix acetate.

AgonistMaleendocrine systemmedicine.medical_specialtyTime Factorsmedicine.drug_classPilot ProjectsGonadotropin-releasing hormoneGonadotropin-Releasing HormoneHormone AntagonistsIn vivoInternal medicinemedicineFlare upHumansTestosteroneEstradiolbusiness.industryGoserelin AcetateAntagonistObstetrics and GynecologyLuteinizing HormoneLong actingEndocrinologyTreatment OutcomeReproductive MedicineCetrorelixGoserelinFemaleFollicle Stimulating Hormone Humanbusinesshormones hormone substitutes and hormone antagonistsTranssexualismmedicine.drugFertility and sterility
researchProduct

Is ovarian stimulation detrimental to the endometrium?

2007

Ovarian stimulation in assisted reproduction technology produces lower implantation rates per embryo transferred than natural and ovum donation cycles, suggesting suboptimal endometrial development due to the abnormal concentrations of hormones used to recruit more oocytes. After the publication of several studies on the gene expression profile of endometrial receptivity in the natural cycle using microarray technology, researchers have investigated the impact of ovarian stimulation on the gene expression pattern of the endometrium. Ovarian stimulation cycles that use gonadotrophin-releasing hormone (GnRH) agonists and antagonists have been analysed in detail during the window of implantati…

Agonistendocrine systemmedicine.medical_specialtymedicine.drug_classStimulationBiologyEndometriumEndometriumOvulation InductionInternal medicineGene expressionmedicineHumansGeneUterine DiseasesObstetrics and GynecologyEmbryoGenomicsmedicine.anatomical_structureEndocrinologyReproductive MedicineGene Expression RegulationGene chip analysisFemaleDevelopmental BiologyHormoneReproductive biomedicine online
researchProduct

Progesterone increases basal 3',5'-cyclic adenosine monophosphate formation and down-regulates the agonist-induced inositol phosphates generation in …

1992

Whether the placenta is a target tissue for estrogens and progesterone, and their putative mechanism of action, is still a controversial question in the literature. The effect of progesterone and estradiol on 3′,5′-cyclic adenosine monophosphate (cAMP) and inositol phosphates generation in human term placenta was investigated. Placental explants were incubated in vitro for up to 48 h in the absence and in the presence of estradiol, progesterone or both steroids (0.1 μmol/l final concentration in all cases), and were stimulated with terbutaline, a β-adrenergic agonist, (0.1 mmol/l) or angiotensin II(1 μmol/l), The cAMP content was measured by a competitive protein binding assay, and the gene…

Agonistmedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismInositol PhosphatesPlacentaDown-RegulationBiologychemistry.chemical_compoundEndocrinologyPregnancyInternal medicinePlacentamedicineCyclic AMPTerbutalineHumansCyclic adenosine monophosphateInositolInositol phosphateProgesteronechemistry.chemical_classificationLabor ObstetricEstradiolAngiotensin IIGeneral MedicineTrypan BlueChromatography Ion ExchangeAngiotensin IIEndocrinologymedicine.anatomical_structurechemistryEstrogenSecond messenger systemLactatesFemaleActa endocrinologica
researchProduct

Probiotics Properties: A Focus on Pregnancy Outcomes.

2021

A healthy microbiome plays an important role in the prevention of illness and maintenance of overall health, including reproductive health. Although the therapeutic advantages of probiotics have been shown to run across multiple organ systems, their role in pregnancy is not well explored. The aim of this review is to highlight the potential advantages and adverse effects of probiotics in pregnancy. Data were collected from the literature over the past decade using PubMed, Medline, Google Scholar, Ovid, Scopus, and Science Direct. A total of 40 articles were utilized in this review. Collected data indicated that prenatal and post-natal supplementation with lactobacilli alone or lactobacilli …

AllergyMicrobiotaProbioticsPregnancy OutcomeObstetrics and GynecologyInfantOpportunistic infectionDiabetes GestationalLactobacillusBreast FeedingReproductive MedicineLactobacilliPregnancyReproductive healthHumansFemaleEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct

Inhibition of Histone Deacetylase Activity in Human Endometrial Stromal Cells Promotes Extracellular Matrix Remodelling and Limits Embryo Invasion

2011

Invasion of the trophoblast into the maternal decidua is regulated by both the trophoectoderm and the endometrial stroma, and entails the action of tissue remodeling enzymes. Trophoblast invasion requires the action of metalloproteinases (MMPs) to degrade extracellular matrix (ECM) proteins and in turn, decidual cells express tissue inhibitors of MMPs (TIMPs). The balance between these promoting and restraining factors is a key event for the successful outcome of pregnancy. Gene expression is post-transcriptionally regulated by histone deacetylases (HDACs) that unpacks condensed chromatin activating gene expression. In this study we analyze the effect of histone acetylation on the expressio…

Anatomy and PhysiologyGene ExpressionHydroxamic AcidsEndometriumEndocrinologyPregnancyMolecular Cell BiologyCells Culturedreproductive and urinary physiologyRegulation of gene expressionMultidisciplinarybiologyQRObstetrics and GynecologyExtracellular MatrixChromatinCell biologyHistonemedicine.anatomical_structureMatrix Metalloproteinase 9embryonic structuresMatrix Metalloproteinase 2MedicineFemaleHistone deacetylase activityResearch Articlemedicine.drugAdultStromal cellScienceDown-RegulationGene Expression Regulation EnzymologicYoung AdultmedicineHumansEmbryo ImplantationBiologyTissue Inhibitor of Metalloproteinase-3Tissue Inhibitor of Metalloproteinase-1Reproductive SystemTrophoblastUrokinase-Type Plasminogen ActivatorMolecular biologyHistone Deacetylase InhibitorsTrichostatin AAcetylationbiology.proteinStromal CellsDevelopmental Biology
researchProduct

P–435 LH preserves oocyte-granulosa cell communication in mouse ovaries exposed to chemotherapy with alkylating agents

2021

Abstract Study question Does Luteinizing Hormone (LH) protect the follicular endowment and growth by improving oocyte-granulosa cell (GC) communication of follicles exposed to chemotherapy at the primordial stage? Summary answer LH treatment protects mouse primordial follicles against alkylating agents by preventing the chemotherapy-induced follicular depletion and the impairment of oocyte-GC communication during follicular growth. What is known already Impaired folliculogenesis is one of the most common deleterious side effects of alkylating agents in ovaries. Bidirectional communication between the oocyte and surrounding GCs is crucial for oocyte development. Therefore, defective gap junc…

AndrologyChemotherapymedicine.anatomical_structureReproductive MedicineChemistrymedicine.medical_treatmentGranulosa cellRehabilitationmedicineObstetrics and GynecologyOocyteHuman Reproduction
researchProduct

Cigarette Consumption and X-Sperm Enrichment After Swim-Up

2005

AndrologyConsumption (economics)Reproductive MedicineObstetrics and GynecologyBiologySpermFertility and Sterility
researchProduct

In vitro fertilization and andrology laboratories in 2030

2021

The in vitro fertilization and andrology laboratories are at the center of assisted reproductive technologies and the place where technicians and embryologists manipulate gametes and preimplantation-stage embryos with the goal of achieving the best embryo for transfer. Through the years, these laboratories have seen developments in technique, technology, and testing. The goal of this Views and Interviews series is to bring together the thought leaders in the field and envision what the laboratories will look like in the next 10 years.

AndrologyEngineeringmedicine.medical_specialtyIn vitro fertilisationReproductive Medicinebusiness.industrymedicine.medical_treatmentmedicineReproductive medicineObstetrics and GynecologyReproductive technologybusinessFertility and Sterility
researchProduct